0000000000001508

AUTHOR

Alois Harder

showing 2 related works from this author

Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy

2003

Renal cell carcinoma (RCC) represents the most common malignant tumor in the kidney and is resistant to conventional therapies. The diagnosis of RCC is often delayed leading to progression and metastatic spread of the disease. Thus, validated markers for the early detection of the disease as well as selection of patients undergoing specific therapy is urgently needed. Using treatment with the monoclonal antibody (mAb) G250 as a model, proteome-based strategies were implemented for the identification of markers which may allow the discrimination between responders and nonresponders prior to application of G250-mediated immunotherapy. Flow cytometry revealed G250 surface expression in approxi…

medicine.drug_classmedicine.medical_treatmentMonoclonal antibodyBiochemistryMass SpectrometryFlow cytometrySequence Analysis ProteinRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalCarcinoma Renal CellMolecular Biologybiologymedicine.diagnostic_testAntibodies MonoclonalProteinsImmunotherapyFlow Cytometrymedicine.diseaseKidney NeoplasmsImmunologyProteomebiology.proteinCancer researchImmunohistochemistryImmunotherapyAntibodyPROTEOMICS
researchProduct

Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma

2005

Renal cell carcinoma (RCC) representing the most common neoplasia of the kidney in Western countries is a histologic diverse disease with an often unpredictable course. The prognosis of RCC is worsened with the onset of metastasis, and the therapies currently available are of limited success for the treatment of metastatic RCC. Although gene expression analyses and other methods are promising tools clarifying and standardizing the pathological classification of RCC, novel innovative molecular markers for the diagnosis, prognosis, and for the monitoring of this disease during therapy as well as potential therapeutic targets are urgently needed. Using proteome-based strategies, a number of RC…

DiseaseBiologyFatty Acid-Binding ProteinsKidneyurologic and male genital diseasesmedicine.disease_causeBiochemistryMetastasisReference ValuesRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalUrotheliumCarcinoma Renal CellneoplasmsMolecular BiologyDNA PrimersKidneyReverse Transcriptase Polymerase Chain ReactionPrognosismedicine.diseaseImmunohistochemistryKidney Neoplasmsfemale genital diseases and pregnancy complicationsGene Expression Regulation Neoplasticmedicine.anatomical_structureImmunologyDisease ProgressionCancer researchUrotheliumCarrier ProteinsCarcinogenesisKidney diseasePROTEOMICS
researchProduct